Charlene JD - Editas Medicine Executive Counsel
| EDIT Stock | USD 2.38 0.06 2.46% |
Executive
Charlene JD is Executive Counsel of Editas Medicine
| Address | 11 Hurley Street, Cambridge, MA, United States, 02141 |
| Phone | 617 401 9000 |
| Web | https://www.editasmedicine.com |
Editas Medicine Management Efficiency
The company has return on total asset (ROA) of (0.3432) % which means that it has lost $0.3432 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7856) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine's management efficiency ratios could be used to measure how well Editas Medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2024. Return On Capital Employed is likely to drop to -0.41 in 2024. Non Current Liabilities Total is likely to gain to about 115.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 40.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Alison Moore | Allogene Therapeutics | 57 | |
| Allan MD | Prime Medicine, Common | 49 | |
| Earl Esq | Allogene Therapeutics | 61 | |
| James JD | Crispr Therapeutics AG | 52 | |
| Edward Rebar | Sana Biotechnology | 56 | |
| JD Esq | Caribou Biosciences | 69 | |
| Jonathan JD | Vertex Pharmaceuticals | 60 | |
| Raju Prasad | Crispr Therapeutics AG | 40 | |
| Eric Schmidt | Allogene Therapeutics | 54 | |
| Gopi Shanker | Beam Therapeutics | N/A | |
| Amy MD | Beam Therapeutics | 60 | |
| Anna MBA | Ginkgo Bioworks Holdings | 34 | |
| Ryan Fischesser | Caribou Biosciences | N/A | |
| Sonja MD | Sana Biotechnology | 49 | |
| Meredith Goldwasser | Prime Medicine, Common | 53 | |
| Karen JD | Prime Medicine, Common | N/A | |
| Stephen Kennedy | Crispr Therapeutics AG | N/A | |
| Karen Tepichin | Ginkgo Bioworks Holdings | N/A | |
| Samarth Kulkarni | Crispr Therapeutics AG | 46 | |
| Jennifer Robinson | Verve Therapeutics | N/A | |
| Yuko JD | Sana Biotechnology | N/A | |
Management Performance
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.34 |
Editas Medicine Leadership Team
Elected by the shareholders, the Editas Medicine's board of directors comprises two types of representatives: Editas Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Editas. The board's role is to monitor Editas Medicine's management team and ensure that shareholders' interests are well served. Editas Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Editas Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gilmore MD, CEO President | ||
| Bruce Eaton, Exec Officer | ||
| Gilmore ONeill, CEO President | ||
| Cristi Barnett, Corporate Relations | ||
| Charlene JD, Executive Counsel | ||
| James Mullen, Chairman of the Board | ||
| Michelle Robertson, Principal CFO | ||
| David Liu, CoFounder Member | ||
| Caren Deardorf, Executive Officer | ||
| Pr Church, CoFounder Member | ||
| Harry III, VP Operations | ||
| Mark Shearman, Ex Officer | ||
| Feng Zhang, CoFounder Member | ||
| Baisong MD, Executive Officer | ||
| Linea Aspesi, Executive Officer | ||
| Linda Burkly, Executive Officer | ||
| CPA CFA, CFO VP | ||
| George Church, CoFounder Member | ||
| Gregory Whitehead, Executive Officer |
Editas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Editas Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (25.18 M) | ||||
| Shares Outstanding | 82.55 M | ||||
| Shares Owned By Insiders | 0.32 % | ||||
| Shares Owned By Institutions | 70.13 % | ||||
| Number Of Shares Shorted | 17.24 M | ||||
| Price To Earning | (7.02) X | ||||
| Price To Book | 1.15 X | ||||
| Price To Sales | 3.26 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.